30.45 USD
+0.41 (+1.36%)
31 USD
+0.55 (+1.81%)
GMAB gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. GMAB has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. GMAB is not valued too expensively and it also shows a decent growth rate. This makes GMAB very considerable for quality investing!
1. Profitability
1.1 Basic Checks
In the past year GMAB was profitable.
In the past year GMAB had a positive cash flow from operations.
In the past 5 years GMAB has always been profitable.
In the past 5 years GMAB always reported a positive cash flow from operatings.
1.2 Ratios
GMAB has a Return On Assets of 21.10%. This is amongst the best in the industry. GMAB outperforms 96.81% of its industry peers.
With an excellent Return On Equity value of 25.76%, GMAB belongs to the best of the industry, outperforming 97.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 17.11%, GMAB belongs to the best of the industry, outperforming 96.62% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for GMAB is below the industry average of 19.19%.
The last Return On Invested Capital (17.11%) for GMAB is above the 3 year average (15.20%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROIC | 17.11% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
1.3 Margins
GMAB has a Profit Margin of 41.35%. This is amongst the best in the industry. GMAB outperforms 97.56% of its industry peers.
In the last couple of years the Profit Margin of GMAB has declined.
Looking at the Operating Margin, with a value of 36.85%, GMAB belongs to the top of the industry, outperforming 97.94% of the companies in the same industry.
GMAB's Operating Margin has declined in the last couple of years.
The Gross Margin of GMAB (94.27%) is better than 93.81% of its industry peers.
In the last couple of years the Gross Margin of GMAB has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% |
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
2. Health
2.1 Basic Checks
GMAB has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, GMAB has less shares outstanding
GMAB has less shares outstanding than it did 5 years ago.
The debt/assets ratio for GMAB is higher compared to a year ago.
2.2 Solvency
GMAB has an Altman-Z score of 11.31. This indicates that GMAB is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 11.31, GMAB belongs to the top of the industry, outperforming 85.37% of the companies in the same industry.
GMAB has a debt to FCF ratio of 0.12. This is a very positive value and a sign of high solvency as it would only need 0.12 years to pay back of all of its debts.
GMAB has a Debt to FCF ratio of 0.12. This is amongst the best in the industry. GMAB outperforms 95.87% of its industry peers.
A Debt/Equity ratio of 0.02 indicates that GMAB is not too dependend on debt financing.
GMAB's Debt to Equity ratio of 0.02 is in line compared to the rest of the industry. GMAB outperforms 42.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Altman-Z | 11.31 |
ROIC/WACC2.46
WACC6.97%
2.3 Liquidity
A Current Ratio of 6.03 indicates that GMAB has no problem at all paying its short term obligations.
GMAB has a Current ratio of 6.03. This is in the better half of the industry: GMAB outperforms 63.79% of its industry peers.
GMAB has a Quick Ratio of 6.01. This indicates that GMAB is financially healthy and has no problem in meeting its short term obligations.
GMAB has a Quick ratio of 6.01. This is in the better half of the industry: GMAB outperforms 64.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 |
3. Growth
3.1 Past
The earnings per share for GMAB have decreased strongly by -50.84% in the last year.
GMAB shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 0.56% yearly.
Looking at the last year, GMAB shows a very strong growth in Revenue. The Revenue has grown by 24.66%.
GMAB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 31.16% yearly.
EPS 1Y (TTM)-50.84%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%-77.72%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
3.2 Future
Based on estimates for the next years, GMAB will show a decrease in Earnings Per Share. The EPS will decrease by -4.19% on average per year.
The Revenue is expected to grow by 14.70% on average over the next years. This is quite good.
EPS Next Y-50.12%
EPS Next 2Y-24.94%
EPS Next 3Y-11.85%
EPS Next 5Y-4.19%
Revenue Next Year22.84%
Revenue Next 2Y19.35%
Revenue Next 3Y17.25%
Revenue Next 5Y14.7%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
GMAB is valuated rather expensively with a Price/Earnings ratio of 17.11.
Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 94.93% of the companies are valued more expensively.
GMAB is valuated rather cheaply when we compare the Price/Earnings ratio to 25.45, which is the current average of the S&P500 Index.
GMAB is valuated correctly with a Price/Forward Earnings ratio of 15.42.
Based on the Price/Forward Earnings ratio, GMAB is valued cheaply inside the industry as 95.50% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of GMAB to the average of the S&P500 Index (34.46), we can say GMAB is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.11 | ||
| Fwd PE | 15.42 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 97.00% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of GMAB indicates a rather cheap valuation: GMAB is cheaper than 96.25% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.57 | ||
| EV/EBITDA | 9.79 |
4.3 Compensation for Growth
The decent profitability rating of GMAB may justify a higher PE ratio.
GMAB's earnings are expected to decrease with -11.85% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)30.54
EPS Next 2Y-24.94%
EPS Next 3Y-11.85%
5. Dividend
5.1 Amount
No dividends for GMAB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
30.45
+0.41 (+1.36%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners38.32%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap18.74B
Revenue(TTM)3.58B
Net Income(TTM)1.48B
Analysts74.62
Price Target62.24 (104.4%)
Short Float %1.79%
Short Ratio4.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.57%
Min EPS beat(2)-86.28%
Max EPS beat(2)25.14%
EPS beat(4)3
Avg EPS beat(4)30.79%
Min EPS beat(4)-86.28%
Max EPS beat(4)134.67%
EPS beat(8)5
Avg EPS beat(8)15.39%
EPS beat(12)7
Avg EPS beat(12)6.4%
EPS beat(16)11
Avg EPS beat(16)21.04%
Revenue beat(2)1
Avg Revenue beat(2)-0.1%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.29%
Revenue beat(4)2
Avg Revenue beat(4)-1.5%
Min Revenue beat(4)-7.66%
Max Revenue beat(4)1.87%
Revenue beat(8)6
Avg Revenue beat(8)146.81%
Revenue beat(12)9
Avg Revenue beat(12)91.32%
Revenue beat(16)9
Avg Revenue beat(16)47.27%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-1.09%
EPS NQ rev (3m)-87.26%
EPS NY rev (1m)4.01%
EPS NY rev (3m)-84.13%
Revenue NQ rev (1m)1.14%
Revenue NQ rev (3m)-84.82%
Revenue NY rev (1m)0.54%
Revenue NY rev (3m)2.7%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.11 | ||
| Fwd PE | 15.42 | ||
| P/S | 5.23 | ||
| P/FCF | 15.57 | ||
| P/OCF | 14.7 | ||
| P/B | 3.26 | ||
| P/tB | 5.14 | ||
| EV/EBITDA | 9.79 |
EPS(TTM)1.78
EY5.85%
EPS(NY)1.97
Fwd EY6.48%
FCF(TTM)1.96
FCFY6.42%
OCF(TTM)2.07
OCFY6.8%
SpS5.82
BVpS9.34
TBVpS5.93
PEG (NY)N/A
PEG (5Y)30.54
Graham Number19.34
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 21.1% | ||
| ROE | 25.76% | ||
| ROCE | 21.02% | ||
| ROIC | 17.11% | ||
| ROICexc | 37.46% | ||
| ROICexgc | 140.29% | ||
| OM | 36.85% | ||
| PM (TTM) | 41.35% | ||
| GM | 94.27% | ||
| FCFM | 33.59% |
ROA(3y)15.92%
ROA(5y)16.24%
ROE(3y)18.48%
ROE(5y)18.5%
ROIC(3y)15.2%
ROIC(5y)16.1%
ROICexc(3y)68.77%
ROICexc(5y)79.83%
ROICexgc(3y)104.16%
ROICexgc(5y)104.49%
ROCE(3y)18.68%
ROCE(5y)19.78%
ROICexgc growth 3Y22.66%
ROICexgc growth 5Y11.4%
ROICexc growth 3Y-22.7%
ROICexc growth 5Y-14.09%
OM growth 3Y-2.13%
OM growth 5Y-7.73%
PM growth 3Y1.23%
PM growth 5Y-2.03%
GM growth 3Y-1.55%
GM growth 5YN/A
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | 0.12 | ||
| Debt/EBITDA | 0.09 | ||
| Cap/Depr | 106.94% | ||
| Cap/Sales | 1.98% | ||
| Interest Coverage | 243.04 | ||
| Cash Conversion | 91.92% | ||
| Profit Quality | 81.24% | ||
| Current Ratio | 6.03 | ||
| Quick Ratio | 6.01 | ||
| Altman-Z | 11.31 |
F-Score7
WACC6.97%
ROIC/WACC2.46
Cap/Depr(3y)96.21%
Cap/Depr(5y)101.76%
Cap/Sales(3y)1.96%
Cap/Sales(5y)2.38%
Profit Quality(3y)107.36%
Profit Quality(5y)103.53%
High Growth Momentum
Growth
EPS 1Y (TTM)-50.84%
EPS 3Y-8.61%
EPS 5Y0.56%
EPS Q2Q%-77.72%
EPS Next Y-50.12%
EPS Next 2Y-24.94%
EPS Next 3Y-11.85%
EPS Next 5Y-4.19%
Revenue 1Y (TTM)24.66%
Revenue growth 3Y32.63%
Revenue growth 5Y31.16%
Sales Q2Q%-81.55%
Revenue Next Year22.84%
Revenue Next 2Y19.35%
Revenue Next 3Y17.25%
Revenue Next 5Y14.7%
EBIT growth 1Y41.76%
EBIT growth 3Y29.8%
EBIT growth 5Y21.02%
EBIT Next Year50.35%
EBIT Next 3Y30.08%
EBIT Next 5Y16.89%
FCF growth 1Y46.62%
FCF growth 3Y51.06%
FCF growth 5Y42.84%
OCF growth 1Y44.68%
OCF growth 3Y47.08%
OCF growth 5Y41.48%
GENMAB A/S -SP ADR / GMAB FAQ
What is the ChartMill fundamental rating of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a fundamental rating of 6 / 10 to GMAB.
What is the valuation status of GENMAB A/S -SP ADR (GMAB) stock?
ChartMill assigns a valuation rating of 6 / 10 to GENMAB A/S -SP ADR (GMAB). This can be considered as Fairly Valued.
Can you provide the profitability details for GENMAB A/S -SP ADR?
GENMAB A/S -SP ADR (GMAB) has a profitability rating of 7 / 10.
What is the valuation of GENMAB A/S -SP ADR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for GENMAB A/S -SP ADR (GMAB) is 17.11 and the Price/Book (PB) ratio is 3.26.
What is the earnings growth outlook for GENMAB A/S -SP ADR?
The Earnings per Share (EPS) of GENMAB A/S -SP ADR (GMAB) is expected to decline by -50.12% in the next year.